Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE- B): 2-year toxicity results from an open- label, randomised, phase 3, non-inferiority trial. (vol 23, pg 1308, 2022)

被引：0
|
作者：
Li, Z.
Liu, P.
Wang, Z.
机构：
来源：
LANCET ONCOLOGY | 2023年 / 24卷 / 05期
关键词：
D O I：
10.1016/S1470-2045(23)00177-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E192 / E192
页数：1
相关论文
共 19 条
  • [1] Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
    Tree, Alison C.
    Ostler, Peter
    van der Voet, Hans
    Chu, William
    Loblaw, Andrew
    Ford, Daniel
    Tolan, Shaun
    Jain, Suneil
    Martin, Alexander
    Staffurth, John
    Armstrong, John
    Camilleri, Philip
    Kancherla, Kiran
    Frew, John
    Chan, Andrew
    Dayes, Ian S.
    Duffton, Aileen
    Brand, Douglas H.
    Henderson, Daniel
    Morrison, Kirsty
    Brown, Stephanie
    Pugh, Julia
    Burnett, Stephanie
    Mahmud, Muneeb
    Hinder, Victoria
    Naismith, Olivia
    Hall, Emma
    van As, Nicholas
    LANCET ONCOLOGY, 2022, 23 (10): : 1308 - 1320
  • [2] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial
    Brand, Douglas H.
    Tree, Alison C.
    Ostler, Peter
    van der Voet, Hans
    Loblaw, Andrew
    Chu, William
    Ford, Daniel
    Tolan, Shaun
    Jain, Suneil
    Martin, Alexander
    Staffurth, John
    Camilleri, Philip
    Kancherla, Kiran
    Frew, John
    Chan, Andrew
    Dayes, Ian S.
    Henderson, Daniel
    Brown, Stephanie
    Cruickshank, Clare
    Burnett, Stephanie
    Duffton, Aileen
    Griffin, Clare
    Hinder, Victoria
    Morrison, Kirsty
    Naismith, Olivia
    Hall, Emma
    van As, Nicholas
    LANCET ONCOLOGY, 2019, 20 (11): : 1531 - 1543
  • [3] Intensity-modulated fractionated radiotherapy vs. stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomized, open-label, phase 3, noninferiority trial
    Grabenbauer, Gerhard G.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (07) : 674 - 675
  • [4] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
    Dearnaley, David
    Syndikus, Isabel
    Mossop, Helen
    Khoo, Vincent
    Birtle, Alison
    Bloomfield, David
    Graham, John
    Kirkbride, Peter
    Logue, John
    Malik, Zafar
    Money-Kyrle, Julian
    O'Sullivan, Joe M.
    Panades, Miguel
    Parker, Chris
    Patterson, Helen
    Scrase, Christopher
    Staffurth, John
    Stockdale, Andrew
    Tremlett, Jean
    Bidmead, Margaret
    Mayles, Helen
    Naismith, Olivia
    South, Chris
    Gao, Annie
    Cruickshank, Clare
    Hassan, Shama
    Pugh, Julia
    Griffin, Clare
    Hall, Emma
    LANCET ONCOLOGY, 2016, 17 (08): : 1047 - 1060
  • [5] Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial (vol 17, pg 1047, 2016)
    Dearnaley, D.
    Syndikus, I
    Mossop, H.
    LANCET ONCOLOGY, 2016, 17 (08): : E321 - E321
  • [6] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial
    Aluwini, Shafak
    Pos, Floris
    Schimmel, Erik
    van Lin, Emile
    Krol, Stijn
    van der Toorn, Peter Paul
    de Jager, Hanja
    Dirkx, Maarten
    Alemayehu, Wendimagegn Ghidey
    Heijmen, Ben
    Incrocci, Luca
    LANCET ONCOLOGY, 2015, 16 (03): : 274 - 283
  • [7] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial
    Aluwini, Shafak
    Pos, Floris
    Schimmel, Erik
    Krol, Stijn
    van der Toorn, Peter Paul
    de Jager, Hanja
    Alemayehu, Wendimagegn Ghidey
    Heemsbergen, Wilma
    Heijmen, Ben
    Incrocci, Luca
    LANCET ONCOLOGY, 2016, 17 (04): : 464 - 474
  • [8] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial (vol 16, pg 274, 2015)
    Aluwini, S.
    Pos, F.
    Schimmel, E.
    LANCET ONCOLOGY, 2015, 16 (03): : E105 - E105
  • [9] Prospective Comparison of Hypofractionated Versus Normofractionated Intensity-Modulated Radiotherapy in Breast Cancer: Late Toxicity Results of the Non-Inferiority KOSIMA Trial (ARO2010-3)
    Sarria, Gustavo R.
    Welzel, Grit
    Polednik, Martin
    Wenz, Frederik
    Abo-Madyan, Yasser
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial
    Wilkins, Anna
    Mossop, Helen
    Syndikus, Isabel
    Khoo, Vincent
    Bloomfield, David
    Parker, Chris
    Logue, John
    Scrase, Christopher
    Patterson, Helen
    Birtle, Alison
    Staffurth, John
    Malik, Zafar
    Panades, Miguel
    Eswar, Chinnamani
    Graham, John
    Russell, Martin
    Kirkbride, Peter
    O'Sullivan, Joe M.
    Gao, Annie
    Cruickshank, Clare
    Griffin, Clare
    Dearnaley, David
    Hall, Emma
    LANCET ONCOLOGY, 2015, 16 (16): : 1605 - 1616
12